← Leaderboards
Kim D Janda
Scripps Research Institute
$47,128,009
Attributed
$47,128,009
Total exposure
48
Grants
38
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,128,009 · 48
By mechanism
R01$26,947,116 · 14
R21$9,676,000 · 19
UH3$4,356,531 · 1
U01$3,839,350 · 3
UH2$1,589,558 · 1
N01$572,289 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseSeriesToxic EffectProteinsScaffoldPharmaceutical PreparationsDesignAntibodiesCellsVaccinesDrug KineticsProductionIn VivoPreventLaboratoriesAffinityReportingLeadAffectDoseSiteAnimal ModelHaptensEvaluation
Grant awards (131)
Preparation and Investigation of Monoclonal Antibodies to Block Xylazine's Mechanism of Action and Adverse Effects$506,000
R21 · FY2025 · DA · contact PI
High-Throughput Screen for the Oncoprotein MYC$399,856
R01 · FY2024 · CA · contact PI
An Enzyme-Based Antidote for Acute Nicotine Toxicity$230,000
R21 · FY2024 · DA · contact PI
Covalent Inhibition as a Method to Counteract Botulinum Intoxication$633,393
R01 · FY2023 · AI · contact PI
High-Throughput Screen for the Oncoprotein MYC$405,757
R01 · FY2023 · CA · contact PI
An Enzyme-Based Antidote for Acute Nicotine Toxicity$271,500
R21 · FY2023 · DA · contact PI
Discovering modulators of exonucleases PLD3 and PLD4 for immunoregulation$221,875
R21 · FY2023 · AI · contact PI
Covalent Inhibition as a Method to Counteract Botulinum Intoxication$634,589
R01 · FY2022 · AI · contact PI
High-Throughput Screen for the Oncoprotein MYC$400,439
R01 · FY2022 · CA · contact PI
Discovering modulators of exonucleases PLD3 and PLD4 for immunoregulation$266,250
R21 · FY2022 · AI · contact PI
Covalent Inhibition as a Method to Counteract Botulinum Intoxication$637,866
R01 · FY2021 · AI · contact PI
Immunotherapy to Counteract Lethal Doses of Carfentanil$516,902
U01 · FY2021 · DA · contact PI
High-Throughput Screen for the Oncoprotein MYC$432,947
R01 · FY2021 · CA · contact PI
Covalent Inhibition as a Method to Counteract Botulinum Intoxication$692,667
R01 · FY2020 · AI · contact PI
Immunotherapy to Counteract Lethal Doses of Carfentanil$513,058
U01 · FY2020 · DA · contact PI
Strategies for the Irreversible Inhibition of Botulinum Neurotoxin$290,250
R21 · FY2020 · AI · contact PI
Chemically-guided Elucidation of Liposomal Tucaresol Immunopotentiation in a Hepatitis C Vaccine$290,250
R21 · FY2020 · AI · contact PI
Immunopharmacotherapy for Mitigating Opioid Addiction$1,470,068
UH3 · FY2019 · DA · contact PI
A Multidisciplinary Approach for the Treatment of Botulinum Intoxication$559,989
R01 · FY2019 · AI · contact PI
Immunotherapy to Counteract Lethal Doses of Carfentanil$520,662
U01 · FY2019 · DA · contact PI
Strategies for the Irreversible Inhibition of Botulinum Neurotoxin$241,875
R21 · FY2019 · AI · contact PI
Chemically-guided Elucidation of Liposomal Tucaresol Immunopotentiation in a Hepatitis C Vaccine$241,875
R21 · FY2019 · AI · contact PI
"PRODUCTION AND DISTRIBUTION OF INVESTIGATIONAL GHRELIN VACCINES-- GHRELIN VACCINES AGAINST RAT HORMONE". TASK ORDER 5. 09/21/2019-12/31/2020.$116,199
N01 · FY2019 · HD · contact PI
Immunopharmacotherapy for Mitigating Opioid Addiction$1,494,700
UH3 · FY2018 · DA · contact PI
A Multidisciplinary Approach for the Treatment of Botulinum Intoxication$561,234
R01 · FY2018 · AI · contact PI
IGF:OT:IGF Production and Distribution of Investigational Ghrelin Vaccines--Ghrelin Vaccine Against Rat Hormone. Task Order 4 HHSN275201500006I/HHSN27500004). 9/21/2018 to 9/20/2019.$125,402
N01 · FY2018 · HD · contact PI
Immunopharmacotherapy for Mitigating Opioid Addiction$976,653
UH3 · FY2017 · DA · contact PI
A Multidisciplinary Approach for the Treatment of Botulinum Intoxication$566,245
R01 · FY2017 · AI · contact PI
Immunopharmacotherapy for Mitigating Opioid Addiction$415,110
UH3 · FY2017 · DA · contact PI
Using Allosteric Inhibition as a Means to Ablate Botulinum Neurotoxin Protease$240,625
R21 · FY2017 · AI · contact PI
Enzympharmacotherapy for attenuating nicotine's psychoactive effects$240,625
R21 · FY2017 · DA · contact PI
IGF::OT::IGF:The Scripps Research Institute. Task Order 3 (HHSN275201500006I/HHSN27500003)."Production and Distribution of Investigational Ghrelin Vaccines--Ghrelin Vaccine Against Rat Hormone. 09/21/$122,391
N01 · FY2017 · HD · contact PI
IGF::OT::IGF:THE SCRIPPS RESEARCH INSTITUTE. TASK ORDER 2 (HHSN275201500006I/HHSN27500002)."PRODUCTION AND DISTRIBUTION OF INVESTIGATIONAL GHRELIN VACCINES--GHRELIN VACCINE AGAINST RAT HORMONE. 09/21/$24,333
N01 · FY2017 · HD · contact PI
Immunopharmacotherapy for Mitigating Opioid Addiction$797,088
UH2 · FY2016 · DA · contact PI
A Multidisciplinary Approach for the Treatment of Botulinum Intoxication$628,233
R01 · FY2016 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$476,437
R01 · FY2016 · DA · contact PI
Using Allosteric Inhibition as a Means to Ablate Botulinum Neurotoxin Protease$288,750
R21 · FY2016 · AI · contact PI
Enzympharmacotherapy for attenuating nicotine's psychoactive effects$240,625
R21 · FY2016 · DA · contact PI
Approaches to Counteract the Harmful Effects of Synthetic Opioid Designer Drugs$238,218
R21 · FY2016 · DA · contact PI
IGF::OT::IGF:THE SCRIPPS RESEARCH INSTITUTE. TASK ORDER 2 (HHSN275201500006I/HHSN27500002)."PRODUCTION AND DISTRIBUTION OF INVESTIGATIONAL GHRELIN VACCINES--GHRELIN VACCINE AGAINST RAT HORMONE. 09/21/$93,963
N01 · FY2016 · HD · contact PI
Immunopharmacotherapy for Mitigating Opioid Addiction$792,470
UH2 · FY2015 · DA · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$466,643
R01 · FY2015 · DA · contact PI
Approaches to Counteract the Harmful Effects of Synthetic Opioid Designer Drugs$284,250
R21 · FY2015 · DA · contact PI
IGF::OT::IGF-SCRIPPS RESEARCH INSTITUTE HHSN275201500006I HHSN275200001$90,001
N01 · FY2015 · HD · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$473,750
R01 · FY2014 · DA · contact PI
Chemical Strategies to Manipulate A1-2 Signaling in Bacterial Pathogens$470,003
R01 · FY2014 · AI · contact PI
Vaccines for the Treatment of Opiate Addiction$460,508
R01 · FY2014 · DA · contact PI
Bacterial Immunosuppression: Host Target Identification Through Chemical Probes$284,250
R21 · FY2014 · AI · contact PI
Exploration of Chitinase Inhibitors for Human Health$236,875
R21 · FY2014 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$442,087
R01 · FY2013 · DA · contact PI
Vaccines for the Treatment of Opiate Addiction$442,087
R01 · FY2013 · DA · contact PI
Chemical Strategies to Manipulate A1-2 Signaling in Bacterial Pathogens$441,802
R01 · FY2013 · AI · contact PI
Investigations Targeting Symptomatic Relief to Botulinum Neurotoxin A Intoxicatio$418,314
R01 · FY2013 · AI · contact PI
Discovery of Small Molecule Probes for Ghrelin O-Acyltransferase (GOAT)$382,193
R01 · FY2013 · DK · contact PI
Exploration of Chitinase Inhibitors for Human Health$284,250
R21 · FY2013 · AI · contact PI
Bacterial Immunosuppression: Host Target Identification Through Chemical Probes$222,663
R21 · FY2013 · AI · contact PI
Chemical Strategies to Manipulate A1-2 Signaling in Bacterial Pathogens$470,003
R01 · FY2012 · AI · contact PI
Vaccines for the Treatment of Opiate Addiction$460,508
R01 · FY2012 · DA · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$460,508
R01 · FY2012 · DA · contact PI
Investigations Targeting Symptomatic Relief to Botulinum Neurotoxin A Intoxicatio$445,015
R01 · FY2012 · AI · contact PI
Discovery of Small Molecule Probes for Ghrelin O-Acyltransferase (GOAT)$396,055
R01 · FY2012 · DK · contact PI
Discovery of Small Molecule Probes for Ghrelin O-Acyltransferase (GOAT)$473,750
R01 · FY2011 · DK · contact PI
Chemical Strategies to Manipulate A1-2 Signaling in Bacterial Pathogens$470,003
R01 · FY2011 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$460,508
R01 · FY2011 · DA · contact PI
Vaccines for the Treatment of Opiate Addiction$460,508
R01 · FY2011 · DA · contact PI
Investigations Targeting Symptomatic Relief to Botulinum Neurotoxin A Intoxicatio$445,015
R01 · FY2011 · AI · contact PI
Chemical Strategies to Manipulate A1-2 Signaling in Bacterial Pathogens$474,750
R01 · FY2010 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$474,750
R01 · FY2010 · DA · contact PI
Vaccines for the Treatment of Opiate Addiction$474,750
R01 · FY2010 · DA · contact PI
Investigations Targeting Symptomatic Relief to Botulinum Neurotoxin A Intoxicatio$449,510
R01 · FY2010 · AI · contact PI
Biological Implications of Tetramic Acid$284,850
R21 · FY2010 · AI · contact PI
MECHANISM OF ACTION OF THE BOTULISM TOXIN$33,501
P41 · FY2010 · RR · contact PI
Investigations Targeting Symptomatic Relief to Botulinum Neurotoxin A Intoxicatio$476,525
R01 · FY2009 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$405,731
R01 · FY2009 · DA · contact PI
Oral Biofilms and the Immune System$284,250
R21 · FY2009 · DE · contact PI
Biological Implications of Tetramic Acid$237,375
R21 · FY2009 · AI · contact PI
AMYLOIDOGENESIS REGULATION BY ACHE IN ALZHEIMER?S DISEASE$3,181
P41 · FY2009 · RR · contact PI
MECHANISM OF ACTION OF THE BOTULISM TOXIN$3,181
P41 · FY2009 · RR · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$405,731
R01 · FY2008 · DA · contact PI
Chemical Studies into the Antibotulinal Properties of Toosendanin$238,997
R21 · FY2008 · AI · contact PI
Oral Biofilms and the Immune System$236,875
R21 · FY2008 · DE · contact PI
MECHANISM OF ACTION OF THE BOTULISM TOXIN$3,233
P41 · FY2008 · RR · contact PI
AMYLOIDOGENESIS REGULATION BY ACHE IN ALZHEIMER?S DISEASE$3,233
P41 · FY2008 · RR · contact PI
Human Monoclonal Antibodies against Botulinum Toxins$419,084
U01 · FY2007 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$406,145
R01 · FY2007 · DA · contact PI
Immunopharmacotherapy as a Strategy to Modify Feeding$315,891
R21 · FY2007 · DK · contact PI
Chemical Studies into the Antibotulinal Properties of Toosendanin$279,600
R21 · FY2007 · AI · contact PI
MECHANISM OF ACTION OF THE BOTULISM TOXIN$1,774
P41 · FY2007 · RR · contact PI
AMYLOIDOGENESIS REGULATION BY ACHE IN ALZHEIMER?S DISEASE$1,773
P41 · FY2007 · RR · contact PI
Human Monoclonal Antibodies against Botulinum Toxins$419,697
U01 · FY2006 · AI · contact PI
Immunopharmacotherapy for the Treatment of Cocaine Abuse$418,275
R01 · FY2006 · DA · contact PI
Catalytic Antibodies as Therapy for Drug Addiction$412,401
R01 · FY2006 · DA · contact PI
Cell-Penetrating Peptide Agents for Cancer Therapy$326,255
R01 · FY2006 · CA · contact PI
Human Monoclonal IgG for Protection against Anthrax$317,852
U01 · FY2006 · AI · contact PI
Immunopharmacotherapy as a Strategy to Modify Feeding$185,900
R21 · FY2006 · DK · contact PI
AMYLOIDOGENESIS REGULATION BY ACHE IN ALZHEIMER?S DISEASE$3,439
P41 · FY2006 · RR · contact PI
High-Throughput Identification of BoNT Inhibitors$1,000,000
R01 · FY2005 · AI
Human Monoclonal Antibodies against Botulinum Toxins$455,681
U01 · FY2005 · AI
Catalytic Antibodies as Therapy for Drug Addiction$422,325
R01 · FY2005 · DA
Cell-Penetrating Peptide Agents for Cancer Therapy$334,106
R01 · FY2005 · CA
Human Monoclonal IgG for Protection against Anthrax$317,177
U01 · FY2005 · AI
A Protein-Polymer Approach to Neural Tissue Regeneration$217,028
R21 · FY2005 · NS
Catalytic Antibodies as Therapy for Drug Addiction$422,325
R01 · FY2004 · DA
Human Monoclonal IgG for Protection against Anthrax$359,237
U01 · FY2004 · AI
Cell-Penetrating Peptide Agents for Cancer Therapy$334,106
R01 · FY2004 · CA
Generating antibodies against N-Acyl homoserine lactones$281,550
R21 · FY2004 · AI
Antibody- and peptide-inhibitors of quorum sensing$281,550
R21 · FY2004 · AI
A BIO-ORGANIC APPROACH TO HUMAN ANTI-GLYCOSYL ANTIBODIES$221,625
R01 · FY2004 · AI
A Protein-Polymer Approach to Neural Tissue Regeneration$217,028
R21 · FY2004 · NS
A new protein-based approach for cocaine abuse treatment$187,700
R21 · FY2004 · DA
Catalytic Antibodies as Therapy for Drug Addiction$422,325
R01 · FY2003 · DA
Immunopharmacotherapy for the Treatment of Cocaine Abuse$370,400
R01 · FY2003 · DA
Cell-Penetrating Peptide Agents for Cancer Therapy$334,106
R01 · FY2003 · CA
Antibody and peptide inhibitors of quorum sensing$281,550
R21 · FY2003 · AI
Generating antibodies against N-Acyl homoserine lactones$281,550
R21 · FY2003 · AI
Biocombinatorial Strategies Against Botulinum Toxin$277,800
R21 · FY2003 · AI
A BIO-ORGANIC APPROACH TO HUMAN ANTI-GLYCOSYL ANTIBODIES$221,625
R01 · FY2003 · AI
A new protein-based approach for cocaine abuse treatment$187,700
R21 · FY2003 · DA
Alzheimer's Disease: Molecular-Based Immunotherapeutics$93,850
R03 · FY2003 · AG
Immunopharmacotherapy for the Treatment of Cocaine Abuse$370,400
R01 · FY2002 · DA
Biocombinatorial Strategies Against Botulinum Toxin$277,800
R21 · FY2002 · AI
A BIO-ORGANIC APPROACH TO HUMAN ANTI-GLYCOSYL ANTIBODIES$221,625
R01 · FY2002 · AI
CATALYTIC ANTIBODIES$157,420
R01 · FY2002 · GM
Immunopharmacotherapy for the Treatment of Cocaine Abuse$310,275
R01 · FY2001 · DA
SOLUABLE POLYMER SUPPORTS FOR ORGANIC SYNTHESIS$263,642
R01 · FY2001 · GM
A BIO-ORGANIC APPROACH TO HUMAN ANTI-GLYCOSYL ANTIBODIES$221,625
R01 · FY2001 · AI
CATALYTIC ANTIBODIES$150,705
R01 · FY2001 · GM
IMMUNOPHARMACOTHERAPY AS A TREATMENT FOR COCAINE ABUSE$88,650
R01 · FY2001 · DA
IMMUNOPHARMACOTHERAPY AS A TREATMENT FOR COCAINE ABUSE$378,513
R01 · FY2000 · DA
SOLUABLE POLYMER SUPPORTS FOR ORGANIC SYNTHESIS$256,878
R01 · FY2000 · GM
CATALYTIC ANTIBODIES$150,705
R01 · FY2000 · GM